



Improving Resilience and Equity in Cervical Cancer Screening: Lessons from COVID-19 and Beyond

November 9, 2020 (1 PM to 5 PM EST), & November 10, 2020 (1 PM to 5 PM EST)

[Nov. 9th Link](#) (PWD Monday!!) [Nov. 10th Link](#) (PWD Tuesday!!)

MEETING OUTCOMES

- Stakeholder input on opportunities, barriers and possible solutions to improve cervical cancer screening during and post COVID-19
- Stakeholder input on barriers included in cross-cutting theme areas

AGENDA

NOVEMBER 9, 2020

- | | |
|--------------------|--|
| 1:00 – 1:10 | AGENDA REVIEW AND ADMINISTRATIVE STATEMENTS
Administrative remarks, facilitator introduces agenda and process |
| 1:10 – 2:00 | PCP WORKING TEAM INTRODUCTION AND PRESENTATION
PCP Introduction, introduce the working team and present work to date on the landscape of opportunities, barriers, and possible solutions |
| 2:00 – 3:00 | CERVICAL CANCER SCREENING IMPROVEMENT OPPORTUNITIES
SESSION 1: PRIORITIZE INCLUSION OF HPV TESTING IN SCREENING <ul style="list-style-type: none">● Reflect on opportunities and barriers● Discuss and contribute ideas on ways to address the most significant barriers |
| 3:00 – 3:15 | BREAK |
| 3:15 – 4:15 | CERVICAL CANCER SCREENING IMPROVEMENT OPPORTUNITIES
SESSION 2: HPV SELF-SAMPLING TO INCREASE ACCESS FOR UNDERSERVED POPULATIONS
Opportunities to improve screening, associated barriers, and possible solutions |
| 4:15– 4:35 | WORKING GROUP REVIEW OF INPUT AND FINAL COMMENTS
Review of the day's stakeholder input and reactions to day's work |
| 4:35 – 5:00 | REVIEW OF INPUT AND FINAL COMMENTS
Review of the day's stakeholder input and reactions to day's work |



NOVEMBER 10, 2020

- 1:00 – 1:15** **AGENDA REVIEW AND ADMINISTRATIVE STATEMENTS**
Administrative remarks, facilitator introduces agenda and process, reflections from day 1
- 1:15 – 2:15** **CERVICAL CANCER SCREENING IMPROVEMENT OPPORTUNITIES**
SESSION 3: USING TECHNOLOGY TO IMPROVE SCREENING MANAGEMENT, AND COMMUNICATION WITH PATIENTS
Opportunities to improve screening, associated barriers, and possible solutions
- 2:15 – 3:15** **CERVICAL CANCER SCREENING IMPROVEMENT OPPORTUNITIES**
SESSION 4: RISK-BASED APPROACH TO SCREENING AND MANAGEMENT
Opportunities to improve screening, associated barriers, and possible solutions
- 3:15 – 3:30** **BREAK**
- 3:30 – 4:30** **CERVICAL CANCER SCREENING IMPROVEMENT OPPORTUNITIES**
SESSION 5: REDUCE SARS-CoV-2 INFECTION RISK IN CLINICAL SETTINGS
Opportunities to improve screening, associated barriers, and possible solutions
- 4:30 – 4:40** **PANEL FINAL COMMENTS**
Brief review of input and panel discussion of next steps
- 4:40 – 5:00** **RESPONSE TO PUBLIC QUESTIONS AND COMMENTS**



Improving Resilience and Equity in Cancer Screening: Lessons from COVID-19 and Beyond

Tumor Type: Cervical Cancer

Monday, November 9 and Tuesday, November 10

Participant List

Deborah Arrindell

Vice President, Health Policy
American Sexual Health
Association
Silver Spring, MD

Jessica L. Bienstock, MD, MPH

Associate Dean for Graduate
Medical Education
Professor of Gynecology and
Obstetrics
Johns Hopkins University School
of Medicine
Baltimore, MD

Haywood Brown, MD

Vice President, Institutional
Equity Associate Dean
Morsani College of Medicine
Professor of Obstetrics and
Gynecology
Division of Maternal-Fetal
Medicine
University of South Florida
Tampa, FL

David Chelmow, MD

Leo J. Dunn Professor and Chair
Department of Obstetrics and
Gynecology
Virginia Commonwealth School
of Medicine
Richmond, VA

Andrew Crighton, MD

Chief Executive Officer
CEO Roundtable on Cancer and
Project Data Sphere
Morrisville, NC

Barbara Crothers, DO

Associate Professor of Pathology
Consultant, Cytology, Gynecology,
and Breast Pathology
Joint Pathology Center
Uniformed Services University of the
Health Sciences
Silver Spring, MD

Katherine Dallow, MD

Vice President and Medical Director
Clinical Programs and Strategy
Health and Medical Management
Blue Cross and Blue Shield of
Massachusetts
Quincy, MA

Tamika Felder

Chief Visionary
Cervivor
Upper Marlboro, MD

Lisa Flowers, MD

Professor, Department of
Gynecology and Obstetrics
Director, Colposcopy and Anoscopy
Emory University School of Medicine
Atlanta, GA

Holly B. Fontenot, PhD, RN/NP

Associate Professor and Frances A.
Mastuda Chair in Women's Health
University of Hawaii at Manoa
School of Nursing
Honolulu, HI

Francisco García, MD, MPH

Deputy County Administrator for
Health & Community Services
Chief Medical Officer, Pima
County
Tucson, AZ



Improving Resilience and Equity in Cancer Screening: Lessons from COVID-19 and Beyond Tumor Type: Cervical Cancer

Monday, November 9 and Tuesday, November 10

Richard Guido, MD
Professor, Obstetrics and
Gynecology
University of Pittsburgh, Magee-
Women's Hospital
Pittsburgh, PA

**Aimee C. Holland, DNP, WHNP-
BC, FNP-C, FAANP**
Associate Professor
Assistant Dean for Graduate
Clinical Education
University of Alabama, Birmingham
School of Nursing
Birmingham, AL

Warner K. Huh, MD
Professor and Margaret
Cameron Spain Endowed Chair
Department of Obstetrics and
Gynecology
University of Alabama, Birmingham
Birmingham, AL

Robert A. Ingram
Member
President's Cancer Panel
General Partner
Hatteras Venture Partners
Durham, NC

Maureen R. Johnson, PhD
Executive Secretary
President's Cancer Panel
Special Assistant
Office of the Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Thomas S. Lorey, MD
Strategic Director, National Integrated
Services
Kaiser Permanente Northern
California Region
The Permanente Medical Group, Inc.
Berkeley, CA

William C. Louv, PhD
President, Project Data Sphere
CEO Roundtable on Cancer
Morrisville, NC

L. Stewart Massad, MD
Professor of Gynecologic Oncology
Department of Obstetrics and
Gynecology
Washington University
St Louis, MO

Edith P. Mitchell, MD, MACP, FCPP
Member, President's Cancer Panel
Clinical Professor of Medicine and
Medical Oncology
Department of Medical Oncology
Director, Center to Eliminate Health
Disparities
Associate Director of Diversity Affairs
Sidney Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA

Karen L. Parker, PhD
Director
Sexual and Gender Minority Research
Office
National Institutes of Health
Bethesda, MD

Rebecca Perkins, MD
Associate Professor of Obstetrics and
Gynecology
Boston University School of Medicine/
Boston Medical Center
Boston, MA

Mona Saraiya, MD, MPH
Medical Officer and Team Lead
Epidemiology and Applied
Research Branch
Division of Cancer Prevention and
Control
Centers for Disease Control and
Prevention
Atlanta, GA



Improving Resilience and Equity in Cancer Screening: Lessons from COVID-19 and Beyond Tumor Type: Cervical Cancer

Monday, November 9 and Tuesday, November 10

Debbie Saslow, PhD
Managing Director
HPV & GYN Cancers
American Cancer Society
Atlanta, GA

Mark Schiffman, MD, MPH
Senior Investigator
Division of Cancer Epidemiology
and Genetics
National Cancer Institute
Rockville, MD

Jane Segebrecht, MPH
Strategic Initiatives Lead
Office of Women's Health
Health Resources and Services
Administration
U.S. Department of Health and
Human Services
Rockville, MD

Robert A. Smith, PhD
Senior Vice President, Cancer
Screening
Cancer Prevention and Early
Detection
American Cancer Society

Mark H. Stoler, MD
Professor (Emeritus) of Pathology
and Clinical Gynecology
Department of Pathology
University of Virginia Health
System
Charlottesville, VA

Sherrie Flynt Wallington, PhD
Assistant Professor, Health
Disparities and Oncology
George Washington University
School of Nursing
Washington, DC

Nicolas Wentzensen, MD, PhD, MS
Senior Investigator
Head, Clinical Epidemiology Unit
Deputy Chief, Clinical Genetics
Branch
Division of Cancer Epidemiology
and Genetics
National Cancer Institute
Bethesda, MD

John P. Williams, MD, FACS
Chair
President's Cancer Panel
Medical Director
Breast Cancer School for
Patients
Gainesville, VA

Amy L. Wiser, MD
Assistant Professor and
Curriculum Director
Undergraduate Medical
Education
Oregon Health & Science
University
Portland, OR

Luna Zaritsky, PhD
Biologist
U.S. Food and Drug
Administration
Silver Spring, MD